Synergetics USA, Inc. (NASDAQ: SURG) ("Synergetics" or the "Company"), a medical device company that designs, manufactures, and markets innovative microsurgical instruments for ophthalmic and neurosurgical applications, today announced its results for the third quarter and nine months ended April 30, 2010. The Company reported an increase in the third quarter 2010 sales to $13.9 million and net income of $3.3 million, or $0.13 per diluted share, compared with the third quarter of fiscal 2009 of $13.1 million in sales, $458,000 in net income and $0.02 per diluted share, respectively.
“Our net income jumped to a record $3.3 million due in part to the gain from the settlement, license and supply agreements with Alcon, Inc. and affiliates ("Alcon”
"Synergetics reported increased sales due to higher demand for our disposable microsurgical products in both domestic and international markets and our higher sales to our marketing partners," stated Dave Hable, President and CEO of Synergetics USA, Inc. "We also reported record net income from operations of $1.2 million ($0.05 per diluted share in our third fiscal quarter ended April 30, 2010 vs. $0.02 in our third fiscal quarter ended May 4, 2009), due to our higher sales, improved gross profit and lower operating expenses.
"Our net income jumped to a record $3.3 million due in part to the gain from the settlement, license and supply agreements with Alcon, Inc. and affiliates ("Alcon") of approximately $2.4 million ($0.06 per diluted share), and the estimated gain from the sale of the Omni® product line to Stryker Corporation ("Stryker") of $893,000 ($0.02 per diluted share), that were completed during our third fiscal quarter. The cash generated from these transactions in addition to the cash flow from operations allowed us to pay down approximately $5.1 million in debt so far and strengthen our balance sheet by adding $17.0 million in cash as of April 30, 2010, since January 31, 2010. In addition, we expect our increased cash position and stronger balance sheet will provide the funding to expand our production capabilities, accelerate development efforts and to explore strategic opportunities.
"We are pleased that our gross profit and operating income increased substantially from last year. We continue to make progress in our operations since we transitioned our direct neurosurgical sales to our marketing partners, focused our research and development programs and implemented lean manufacturing initiatives. We remain focused on these programs to support our continued growth opportunities," continued Mr. Hable.
Third Quarter Results
Third quarter 2010 sales rose 5.3% to $13.9 million compared with $13.2 million in the third quarter of 2009. The increase in third quarter sales from last year was due primarily to higher sales of disposal microsurgical products, including higher sales to our marketing partners Codman & Shurtleff, Inc. ("Codman") and Stryker. Although sales of capital equipment product lines remained soft due to the weak economy and continued budget constraints for new capital goods purchases, higher sales of disposable products more than offset this decline.
- Total ophthalmic sales rose 4.0% to $7.8 million in the third quarter of fiscal 2010 compared with $7.5 million in the third quarter of fiscal 2009. International ophthalmic sales increased 13.5% while domestic ophthalmic sales decreased 3.0%. The growth in international ophthalmic sales benefitted from expanded markets, higher volume sales of disposable products and price increases.
- Total neurosurgical sales, including sales to marketing partners increased to $3.9 million in the third quarter of fiscal 2010 compared with $3.6 million in the third quarter of fiscal 2009. Direct neurosurgical sales declined to $2.0 million in the third quarter of fiscal 2010 compared with $3.6 million in the third quarter of fiscal 2009, primarily due to the transition of sales of neurosurgical products to Codman and Stryker under newly-signed marketing partner agreements. New sales to our marketing partners totaled $1.8 million in the third quarter of fiscal 2010, more than offsetting the loss in direct neurosurgical sales. Codman began selling Synergetics' proprietary disposable bipolar forceps in domestic markets effective December 1, 2009, and expanded sales to international markets effective February 1, 2010.
- Total OEM sales rose 12.2% to $2.2 million compared with $2.0 million in the third quarter of fiscal 2009. There were no sales to Alcon in the third quarter of fiscal 2010. Sales to Alcon under the newly-signed agreements for certain Synergetics' patented ophthalmic products are expected to begin in fiscal 2011.
Gross profit for the third quarter of fiscal 2010 rose to $8.0 million, or 57.9% of sales, compared with $7.4 million, or 56.2% of sales, in the same period in fiscal 2009. Gross profit as a percentage of net sales for the third quarter of fiscal 2010 compared to the third quarter of fiscal 2009 increased approximately 2 percentage points, primarily due to the favorable change in mix to domestic sales from the increase in sales to our marketing partners and improved absorption of labor due to lean manufacturing initiatives.
Operating income for the third quarter of fiscal 2010 increased to $2.0 million compared with $879,000 in the third quarter of fiscal 2009. The increase in operating income benefited from higher gross profits and lower sales and marketing expenses as sales of neurosurgery products were transitioned to marketing partners.
Research and development ("R&D") expenses rose to $886,000 in the third quarter of fiscal 2010 due partly to increased funding of the Pinnacle 360oTM ("Pinnacle") forceps project and other focused R&D projects. The Pinnacle product line was launched in the third quarter. Pinnacle is a fully disposable line of hand-held instruments for retinal surgery that features an actuation grip allowing the surgeon to approach the retina from any angle. The Pinnacle products are being evaluated by a number of major accounts and the Company expects to report positive results in subsequent quarters.
"Our growth in neurosurgical sales highlights the potential of our expanded distribution network through our neurosurgery marketing partners," noted Mr. Hable. "Marketing partner sales to Codman and Stryker have ramped up to $1.8 million during the third fiscal quarter since we signed the exclusive marketing agreements. We have partnered with the leading companies in the neurosurgical markets to sell our proprietary products. We expect sales to Codman and Stryker to build in future quarters as a result of these new agreements. We will also be working with Codman and Stryker on certain development projects. We are very enthusiastic about the potential of these new agreements and the opportunity to increase our neurosurgical market share through our marketing partners. With respect to our ophthalmic distribution network, including our current direct sales organization, we have no plans to eliminate this core company asset nor are we planning on transferring any of our ophthalmic business to marketing partners.
"The jump in our operating income this quarter demonstrates the leverage we have achieved by utilizing our marketing partners to sell and distribute our neurosurgical products," continued Mr. Hable. "Our sales and marketing expenses are down almost 19% from the third quarter of last year while our gross margin improved approximately 2 points."